Search This Blog

Friday, December 31, 2021

S.Africa lifts curfew as it says Covid omicron peak has passed

 South Africa lifted a midnight to 4 a.m. curfew on movement with immediate effect as it believes the country has passed the peak of its fourth Covid-19 wave driven by the Omicron variant, a cabinet statement said on Thursday.

South Africa, which is currently at the lowest of its five-stage Covid-19 alert levels, made the changes based on the trajectory of the pandemic, levels of vaccination in the country and available capacity in the health sector.

Besides lifting the restrictions on public movement, the government said gatherings will be restricted to no more than 1,000 people indoors, and no more than 2,000 people outdoors.

It also ruled that alcohol shops with licenses to operate beyond 11 p.m. (2100GMT) may revert back to full license conditions, a welcome boon for traders and business hard hit by the pandemic and looking to recover during the festive season.

“While the Omicron variant is highly transmissible, there has been lower rates of hospitalisation than in previous waves. This means that the country has a spare capacity for admission of patients even for routine health services,” the cabinet said.

https://www.cnbc.com/2021/12/30/south-africa-lifts-curfew-as-it-says-covid-fourth-wave-has-passed-the-peak.html

CES to Now End Sooner Than Planned as Omicron Cases Surge

 CES will now end a day earlier than planned, the organizer of the global technology and gadget show said, after companies including Amazon.com Inc and General Motors Co dropped out of attending the Las Vegas event in person due to Omicron concerns.

"The step was taken as an additional safety measure to the current health protocols that have been put in place for CES," the event organizer Consumer Technology Association (CTA) said on Friday, announcing the event will now end on Jan. 7.

The spread of the highly transmissible Omicron variant has led to a sharp jump in COVID-19 infections across the world, making many reconsider their travel plans and leading to thousands of flight cancellations.

The number of new COVID-19 cases in the U.S. has doubled in eight days to a record high of 329,000 a day on average, according to a Reuters tally.

As worries over the new variant loom, many companies have withdrawn from presenting in-person at the event, planned both virtually and in-person, that begins on Jan.5 with over 2,200 exhibitors.

Over the last few days, a host of firms including Advanced Micro Devices, Procter & Gamble, Alphabet Inc's Google, Facebook parent Meta Platforms have also dropped their in-person plans.

Sony Group's Sony Electronics has said it will have limited staffing and attendees at the event.

All attendees in Las Vegas will be required to be fully vaccinated and masked. COVID-19 test kits will also be provided at the venue, according to CTA's statement.

https://money.usnews.com/investing/news/articles/2021-12-31/ces-to-now-end-sooner-than-planned-on-omicron-concerns

How easy will health insurers make it to get free, at-home COVID-19 tests?

 Trying to get screened for COVID-19 before the holidays, Gia Ingenito stood in a long line at a free testing site in a park two blocks from the White House last week.

The free, at- at her neighborhood library had been snapped up in minutes.

So she patiently waited in the December chill, on the day President Joe Biden announced new measures to make at-home tests more available—although not until January.

Next month, Americans will be able to request free tests from a website and kits will be mailed to homes.

The website, and other details about how and when the tests will be distributed, have not been released.

Also still to come are the parameters for how private health insurers will have to pick up the tab for over-the-counter tests, a requirement Biden announced at the beginning of December as the highly infectious omicron variant was just starting to spread.

If consumers have to seek reimbursement from the insurer after buying a test, rather than getting it free at the pharmacy, that would be "better than nothing," said Ingenito, 37, an executive assistant at an accounting firm.

"But it's another deterrent," she added.

Ingenito said it would be "ideal" if consumers could just show an  when picking up an at-home test at the pharmacy, similar to how she provided her insurance information at the city's free site.

She's not alone in that view.

Experts urge fewer hurdles

It's not clear yet if the White House plan will require consumers to seek reimbursement from insurers, or if insurers will work with pharmacies to make the tests free to consumers up front.

Several top health experts have urged the latter approach. They say that requiring reimbursement would create additional hurdles for consumers, who would have to save receipts, submit them and wait to get their money back. And the U.S. can't afford a burdensome process at a time when infections are rising, the demand for testing is higher than ever, and people are gathering inside during the winter months.

"If you are somebody who is struggling to make ends meet and they're being asked to spend some of your own money to buy rapid tests and then wait for reimbursement, that's really not even going to be an option for people even if they do get reimbursed," said Dr. Celine Gounder, an epidemiologist who advised Biden's transition team on COVID-19.

But insurers might not want to make it too easy to get the free tests. Extensive use could escalate their costs and  have warned those bills could a be passed along to consumers through higher premiums.

Ensuring that Americans can get tested easily and affordably is a central part of the administration's strategy to reduce the spread of the coronavirus without shutting schools and businesses. But in addition to the cost obstacle, tests are in short supply. Retailers have been limiting how many can be purchased at a time.

"One of the other things that we know that has to be done is more testing," Biden said when announcing new measures to help. "And on that score, we are not where we should be."

Adrienne McCray, a 47-year-old landscape architect who put an hour's worth of money into her parking meter before getting in line for a COVID-19 test Tuesday, said she would use her  to get an at-home test even if it meant having to seek reimbursement after purchase. But she thinks many others will bypass that option.

"It just needs to be more accessible all around," McCray said of testing.

Insurers can make it easier or harder

Jeff Zients, the White House COVID-19 response coordinator, said last week that all ideas, including requiring insurers to work with pharmacies so people don't have to file for reimbursement, are "on the table."

"That'll be worked through across the next couple of weeks with clear guidance on how American consumers with private health insurance can be easily reimbursed for their test," Zients said during the COVID team's final briefing before Christmas.

Without a mandate, insurance companies will decide how easy they want it to be for consumers to buy tests, said Larry Levitt, executive vice president for health policy at the Kaiser Family Foundation, a non-partisan research organization.

"My guess is they're going to make it hard, not easy, for people to get them," he said. "The cost could end up being substantial."

Insurers are already required to pay for COVID-19 tests administered at testing sites and medical offices, which can cost $100 or more. Home-tests, which consumers can buy without a prescription at retail stores or online, are less expensive. Walmart sells the BinaxNow kit for $14. Others cost $25 or more.

The cumulative cost would quickly mount if the more than 150 million people with private insurance want to test themselves weekly, or even more often, with at-home kits.

Despite what insurers are already spending on pandemic-related costs, however, Levitt said they have "still done quite well" financially.

Insurers already have options

Even before Biden's announcement, Express Scripts, one of the nation's largest pharmacy benefit managers, announced it's offering health plans the option of covering over-the-counter COVID-19 test kits through their existing pharmacy benefit plans.

If insurers go along, consumers could use their Express Scripts member ID card to pick up tests at participating in-network pharmacies starting in January.

Express Scripts didn't respond to questions about whether insurers have expressed interest in that option.

A spokesman for the trade association representing pharmacy benefit managers deferred questions about the Biden administration's reimbursement requirement to insurance companies.

Kristine Grow, spokeswoman for America's Health Insurance Plans, said it's too soon for her trade association to comment on "potential approaches until we receive further guidance from the administration."

When Biden's reimbursement requirement was announced in early December, Grow said that while ensuring everyone has access to affordable testing is an important tool to fighting the pandemic, the reimbursement requirement could also lead to manufacturers hiking the cost of the tests and higher insurance premiums.

"As we continue our work with the administration in the fight against COVID-19," Grow said at the time, "we will make sure that the full impact of these actions on patients, consumers, and hardworking families is understood."

The nation's pharmacies might also oppose any effort to nix the up-front consumer payment requirement. Drug stores are fine with selling the tests, but they're concerned that having to work out payments with insurers, instead of customers, will burden pharmacists who are already strapped by the pandemic.

"From the patient standpoint, absolutely, it would be easy and probably more accessible," said Hannah Fish, director of strategic initiatives for the National Community Pharmacists Association, said of having pharmacists get paid by health plans rather than consumers. "From a pharmacy standpoint, it would actually make it a little more challenging."

Testing services tend to be covered on the medical benefit side of health insurance rather than the prescription side, Fish said. And reimbursements on the medical side are not as straightforward—and are often delayed, she added.

Plus, not every pharmacy has a contract with all insurance plans, and tests don't have to be purchased in pharmacies; some will be purchased online or through other retailers.

Experts say the White House's testing plan should be driven by what will deliver the biggest public health benefit, not what hurdles it might create for insurers and pharmacies. Any obstacles for consumers will have a negative impact on their ultimate goal: Getting the pandemic under control.

"If consumers face out-of-pocket costs, even if they're relatively cheap, the likelihood is that they won't use the tests," said Rena Conti, associate professor at the Questrom School of Business.

She said decades of economic research shows that the default option matters. So if consumers have to seek reimbursement, inertia will set in and they won't do it.

Waiting for White House guidance

Sabrina Corlette, a co-director of the Center on Health Insurance Reforms at Georgetown University's McCourt School of Public Policy, said insurers might actually find it easier to deal with pharmacies and pharmacy benefit managers instead of consumers.

"There's not just the cost to the carrier in terms of cutting the checks," she said. "It's a hassle factor for them too, to be collecting all these receipts."

Still, she said, "so much depends on the guidance that the administration puts out next month."

Health and Human Services Secretary Xavier Becerra said there is always the possibility that insurers could challenge the reimbursement requirement, similar to how the administration's mandate that larger employers ensure their workers are either vaccinated or regularly tested is now before the Supreme Court.

"We've done what we think our authorities allow us to do. Now we've got to see it play out," Becerra told reporters this month. "So if an insurer says, 'I'm not paying for it,' we'll test that out."

Micah Johnson, who was waiting for a COVID-19 test last week to "take every precaution" before seeing his granddaughter, had spent 20 minutes on hold trying to find a testing site before lining up in the park.

Johnson, 73, welcomed more options but feels the government has been more reactive than proactive in dealing with the pandemic.

"It is what it is," Johnson concluded. "I'm just going to do my part—and try to take advantage of what is available."

https://medicalxpress.com/news/2021-12-easy-health-free-at-home-covid-.html

Pediatric hospitalizations up under Omicron, but it's not more severe

 New pediatric COVID hospitalizations have hit a record-high in the United States, as children are increasingly swept up in Omicron's lightning spread.

While experts are concerned, and stress the need to step up vaccination among kids, early indications suggest that the new variant's rate of severe disease could in fact be lower, and its extreme contagiousness is behind the rapid rise.

The raw data might also be muddied by coincidental infections that aren't the main cause of a hospital admission.

Numbers spiking

According to the American Academy of Pediatrics, almost 199,000 children were reported infected with COVID-19 in the week ending December 23, the last week for which data is currently available, and a 50 percent rise on figures earlier in the month.

The seven-day-average of COVID hospital admissions for people aged 0-17 was 378 in the week ending December 28, a 66.1 percent increase on the prior week and the highest ever figure, surpassing the previous peak seen during the Delta wave on September 1, per official data.

The only other age group where hospitalizations have hit a new peak are 18-29 year olds.

The rates of severe illness remain however much lower in absolute terms compared to older age groups.

There have been 803 deaths of people aged 0-18 from COVID in the US, out of more than 820,000, since the pandemic began.

Early research out of Hong Kong based on lab testing of tissue samples has shown Omicron replicates up to 70 times faster in the bronchi, the airways leading into the lungs, compared to Delta, which may help explain its extreme spread throughout the population.

"I think at this point, it's a numbers game," Jim Versalovic, a pathologist and immunologist at Texas Children's Hospital, the largest children's hospital in the United States, told AFP.

"Based on what we've gathered today, Omicron is not causing more severe infections, but is infecting many more children. And hence we are seeing more children hospitalized with COVID," he added.

If anything, there appears to be a greater proportion of mild pediatric cases linked to Omicron—which is similar to what has been seen in adults, he added.

Its relative mildness could be explained by the same Hong Kong study that showed Omicron replicated 10 times slower in the lungs compared to Delta, and a hamster study from the University of Tokyo has borne this out.

But "even if you have a small percentage of kids that would have severe disease, a small percentage of a large number is a large number," Henry Bernstein, a pediatrician at Northwell Health hospital system in New York told AFP.

As to why the rate of cases, and thus hospitalizations, are rising faster in younger age groups compared to older, there are several potential factors at play.

President Joe Biden's chief medical advisor Anthony Fauci told reporters this week that "many children are hospitalized with COVID as opposed to because of COVID."

In other words, since hospitals are routinely COVID testing everyone admitted, they are picking up coincidental coronavirus infections.

The vaccination rate is also lowest among children aged 5-11, who were the last group to become eligible, in November.

According to figures from the Centers for Disease Control and Prevention (CDC), only 15 percent of this group is fully vaccinated, compared to 84 percent of people aged 12 and over.

Vaccination strongly recommended

The take home message for parents, according to Versalovic, is "there's no time to waste in getting a vaccine"—and that goes for the whole family, including adults, who could spread to their kids, added Bernstein.

In fact, the hospitalized adolescents Versalovic's hospital has seen are "almost exclusively unvaccinated."

The case for vaccinating young  was strengthened by a new CDC report out Thursday that found serious side effects were exceedingly rare in 5-11 year olds. Feared cases of heart inflammation occurred even less frequently than in males aged 12-29.

Only infants aged 0-5 remain ineligible for vaccines, with expectations for authorization in the coming months.

Versalovic added there was also cause for hope that the spike might recede very quickly in the coming weeks, as was seen in southern Africa.

https://medicalxpress.com/news/2021-12-pediatric-hospitalizations-omicron-severe.html

Severe illness, viral coinfection common in children with COVID-19 hospitalization

 Many pediatric patients with COVID-19-related hospitalization have severe illness, according to research published in the Dec. 31 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Valentine Wanga, Ph.D., from the CDC COVID-19 Response Team, and colleagues reviewed medical record data for patients younger than 18 years with COVID-19-related hospitalizations during July to August 2021. Of the 915 patients identified, 713 were hospitalized for COVID-19, 177 had an incidental positive severe acute respiratory syndrome coronavirus 2 test result (unrelated to hospitalization), and 25 had multisystem inflammatory syndrome in children.

The researchers found that of the 713 patients hospitalized for COVID-19, 24.7, 17.1, 20.1, and 38.1 percent were aged younger than 1, 1 to 4, 5 to 11, and 12 to 17 years, respectively. About two-thirds (67.5 percent) had one or more underlying medical condition, most commonly obesity (32.4 percent); 61.4 percent of those ages 12 to 17 years had obesity. Overall, 15.8 percent of patients hospitalized for COVID-19 had a viral coinfection (66.4 percent had respiratory syncytial virus infection). Only one of the 272 vaccine-eligible patients hospitalized with COVID-19 was fully vaccinated (0.4 percent). Of the patients hospitalized for COVID-19, 54.0, 29.5, and 1.5 percent received oxygen support, were admitted to the , and died, respectively. Of those requiring respiratory support, 14.5 percent needed invasive mechanical ventilation.

"These data highlight the importance of COVID-19 vaccination for those aged ≥5 years and other prevention strategies to protect children and adolescents from COVID-19, particularly those with obesity and other underlying health conditions," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; one author reports application of a patent with a pharmaceutical company.


Explore further

Severe COVID-19 outcomes not up during Delta predominance

More information: Abstract/Full Text

Immune response to seasonal coronaviruses may offer protection against COVID-19

 A research group led by Shin-ichiro Fujii of the RIKEN Center for Integrative Medical Sciences have found that individuals with a certain HLA type may be able to mount a killer T cell response to COVID-19, thanks to the T cells responding to a portion of the virus's spike protein that is also present in seasonal coronaviruses that cause the common cold. This work, published in Communications Biology, could help explain the different responses between populations, and could potentially be used as a way to develop a new type of vaccine against the disease.

Up until now, most of researchers have focused on the antibody response to the , which prevents initial infection. However, once the virus infects cells, to eliminate viruses quickly, effector lymphocytes—NK cells or memory T cells—become critical. Based on the consideration that NK cell response should be relatively similar across people, they decided to focus on memory killer T cells, which lead an attack against viruses that they "remember."

The authors chose to look at individuals with HLA type A24, a type that is relatively common in Japanese and some populations in other countries including several Asian countries. According to Fujii, this choice was made because it was easy to find individuals with this HLA type, as others are much less common, and also because they felt it might offer insights into why some populations in Asia have appeared to be less susceptible to the infections.

The group began by using in silico analysis to look for parts of the SARS-CoV-2 spike protein that can bind highly with HLA-A24. As a result, they identified six potential epitopes—sequences of amino acids that immune cells respond to. They then looked at the reaction of peripheral  in people with the HLA-A24 type who had not been infected with SARS-CoV-2, to see whether they had memory killer T cells that would respond to antigens from the virus. In fact, around 80 percent of uninfected healthy donors with the A24 type HLA did show a reaction for a single peptide—a sequence they called the QYI epitope—which they identified. Finally, they found that QYI-specific memory killer T cells from donors with the A24 serotype showed cross-reactivity against the relevant epitopes, which are relatively conserved from human coronaviruses including seasonal coronaviruses.

The group then looked at the response in patients with , who are known to be particularly susceptible to serious COVID-19. The response was much smaller than those from non-exposed healthy individuals. Importantly, however, the group discovered that even in patients with blood cancers, there is a "hotspot," located in the spike protein of the virus—a sequence of 27 amino acids around the QYI epitope—and that T cells responding to this can still mount a vigorous immune response. For the hotspot, 100 percent of healthy people and 65 percent of blood cancer patients responded. According to Fujii, "This leads to the hope of developing vaccines that could boost the immune response even in immunocompromised patients.

The real goal of this work, says Fujii, is not to find differences between population but rather to find ways to prevent people from dying of the disease. "The real hope," he says, "is that we will be able to develop vaccines that can stimulate a strongly targeted reaction by T  against the infection. We have demonstrated that this could be possible in this particular HLA group, but now need to look at other types."


Explore further

Study shows vaccines may protect against new COVID-19 strains—and maybe the common cold

More information: Kanako Shimizu et al, Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2, Communications Biology (2021). DOI: 10.1038/s42003-021-02885-6
https://medicalxpress.com/news/2021-12-immune-response-seasonal-coronaviruses-covid-.html

NYC private schools preparing for COVID-19 upheaval when students return

 The city’s top private schools are bracing for COVID upheaval with classes set to resume next week amid a surge in cases.

Elite bastions including Spence and Horace Mann are implementing new vaccine mandates, specifying acceptable mask types and requiring negative COVID-19 to for kids to return to school.

Spence canceled classes Monday to provide parents a free day for kids to get tested.

“I realize how challenging a no-school call can be for families, and I appreciate your support and understanding,” wrote Spence chief Bodie Brizendine in a letter to families. “For all of us this is about staying safe and staying in school, and this is the best possible option for both.

The Collegiate School in Manhattan is joining other city private schools in requiring eligible students to get fully vaccinated — and boosted — to remain eligible for enrollment.

The school is also mandating that students get a negative COVID-19 test at the beginning of each week in order to come to class.

Collegiate is increasing student testing each week and updated its masking policy.

Horace Mann School in the Bronx, NY.
Horace Mann School in the Bronx will be providing COVID-19 tests to children before classes begin.
James Messerschmidt

“Masking continues to be required, yet cloth masks are no longer sufficient during this highly transmissible Omicron surge,” said head of school David Lourie, who noted that there were 23 cases reported among students and staff over the winter break. “Everyone must wear a medical-grade disposable mask, such as an N95, KN95, KJ94 or a surgical mask.”

Collegiate will also “expedite” lunch to minimize the amount of time students take off their masks in order to consume their food.

Exterior of Collegiate School, located at 301 Freedom place, Manhattan.
The Collegiate School in Manhattan plans on shortening lunch breaks when students are allowed to remove their masks.
Robert Miller

Horace Mann Head of School Thomas Kelly told parents that the Bronx school will offer COVID-19 tests to kids on Sunday and Monday at the school before classes resume on Tuesday.

Meanwhile, an increasing number of teachers unions have pressed to transition to remote learning due to the coronavirus resurgence.

Chicago’s teachers union has threatened to strike if officials don’t agree to implement remote learning and to increase recurrent testing.

A woman and a child wear masks in Manhattan during the outbreak of the Omicron variant of Covid-19.
Collegiate School head David Lourie says students must wear a “medical-grade disposable mask” to stop the Omicron variant from spreading.
Stephen Yang

A total of six New Jersey districts will have kids learning from home when classes resume next week.

The city announced new testing protocols for students this week — but incoming Mayor Eric Adams has said that he doesn’t foresee closing schools or switching to remote learning.

https://nypost.com/2021/12/31/nyc-private-schools-preparing-for-covid-19-surge-after-holidays/